Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

Super Micro has until Tuesday to file delayed financial accounts or risk being delisted by the Nasdaq stock exchange, ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...

Hims & Hers delivered Q4 2024 earnings that saw the stock sell off nearly 20% after hours. Find out why I rate HIMS stock a ...

We recently published a list of 10 Stocks Grow Firmer Despite Mixed Market Sentiment. In this article, we are going to take a ...

Hims & Hers Health (HIMS) stock crashes even as the company reported better than expected Q4 2024 results and issued a bullish outlook. Read more here.

Hims & Hers Health reports its fourth-quarter results after Monday's closing bell. Here's a look at the key figures from the ...

Needham raised the firm’s price target on Hims & Hers to $61 from $31 and keeps a Buy rating on the shares. The company reported strong Q4 ...